Glucotrack, Inc. (GCTK) stock
Close on Oct 19, 2026Market cap $3.43MP/E 0.0Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $3.43M
- P/E ratio
- 0.0
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -447.15%
Fundamentals
- Net income
- -$15.95M
- EPS, diluted
- $31.22
- Free cash flow
- -$15.34M
- Book value per share
- -$0.35
- Diluted shares
- 5M
Trading
- Previous close
- $0.72
- Open
- $0.74
- Day's range
- $0.68 – $0.74
- Volume
- 102,790
- Average volume (20 days)
- 4,343,118
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | GCTK | S&P 500 | Difference | GCTK per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -72.3% | +0.6% | −72.9 pts | ||
| 3 months | -90.7% | +3.4% | −94.1 pts | ||
| Year to date | -98.8% | +13.3% | −112.1 pts | ||
| 1 year | -99.3% | +16.6% | −115.9 pts | ||
| 3 years | -100.0% | +86.4% | −186.4 pts | -96.8% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.9 pts | -93.2% | +12.7% |
| 10 years | -100.0% | +318.9% | −418.9 pts | -78.3% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Glucotrack filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- Update
- Update
- Update
About Glucotrack
Surgical & Medical Instruments & Apparatus
Glucotrack, Inc. is a medical device company focused on developing an implantable continuous blood glucose monitoring system, the Glucotrack CBGM. Designed for individuals with Type 1 diabetes as well as individuals with Type 2 diabetes who use insulin or are at risk for hypoglycemia, the system requires no additional wearable component. The device uses an intravascular design featuring a subcutaneously implanted unit connected to a lead inserted directly into a blood vessel to provide continuous blood glucose measurements. The company also investigates glucose sensing in the epidural space for patients considering spinal cord stimulation.
Company profile, executives and historyGlucotrack stock: common questions
What is Glucotrack's stock price?
GCTK closed at $0.68 on Oct 19, 2026, down 5.56% on the day.
What is Glucotrack's market cap?
Glucotrack was worth $3.43M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is GCTK's P/E ratio?
GCTK trades at 0.0 times earnings, based on diluted earnings per share of $31.22 over fiscal 2025.
Does Glucotrack pay a dividend?
No. Glucotrack has not paid a cash dividend over the last twelve months.
How has GCTK stock performed over the past year?
Including dividends, GCTK returned -99.3% over the past year, against +16.6% for the S&P 500.
Who are Glucotrack's competitors?
Companies most similar to Glucotrack by business, industry and size include MODD, DXCM, PODD, PFSA, BBNX.
See a number that looks wrong?